Saba discloses 7.88% HQL stake in abrdn Life Sciences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein filed Amendment No. 9 to Schedule 13D reporting beneficial ownership of 2,274,356 common shares of abrdn Life Sciences Investors (HQL), equal to 7.88% of the outstanding shares based on 28,872,416 shares outstanding as of 3/31/25. The event triggering this filing occurred on 11/21/2025.
All reporting persons share voting and dispositive power over these shares and have no sole voting or dispositive authority. Approximately $29,826,505 was paid to acquire the reported position, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. Funds and accounts advised by Saba Capital are entitled to dividends and sale proceeds. This amendment updates Items 3, 5 and 7, and lists Schedule A as an exhibit detailing recent open-market transactions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in HQL does Saba Capital report in this Schedule 13D/A?
Who are the reporting persons in the HQL Schedule 13D/A Amendment No. 9?
How much did Saba Capital pay to acquire its HQL position?
How was the HQL investment by Saba Capital funded?
What is the date of the event requiring this HQL Schedule 13D/A filing?
Which items are amended in this HQL Schedule 13D/A Amendment No. 9?
AI-generated analysis. How Rhea-AI works. Not financial advice.